Hepatobiliary Scintigraphy and Glass ⁹⁰Y Radioembolization with Personalized Dosimetry: Dynamic Changes in Treated and Nontreated Liver

Abstract

Background: The functional changes that occur over time in the liver following 90Y-radioembolization (RE) using personalized dosimetry (PD) remain to be investigated. Methods: November 2016–October 2019: we retrospectively included hepatocellular carcinoma (HCC) patients treated by 90Y-glass RE using PD, who underwent hepatobiliary scintigraphy (HBS) at baseline and at 15 days, 1, 2, 3, and 6 months after RE. Results: There were 16 patients with unilobar disease (100%) included, and 64 HBS were performed. Whole liver function significantly decreased over time. The loss was maximal at 2 weeks: −32% (p = 0.002) and remained below baseline at 1 (−15%; p = 0.002), 2 (−25%; p p = 0.027). No radioembolization-induced liver disease was observed. Treated liver function strongly decreased to reach −64% (p p = 0.027) and remained below baseline before reaching +20% (p = 0.002) and +59% (p p = 0.01) but independent evolutions in the nontreated livers (p = 0.08). Conclusion: RE using PD induces significant regional changes in liver function over time. As early as 15 days following RE, both the treated and nontreated livers showed a decreased function. Nontreated liver function recovered after 3 months and greatly increased afterwards.

Keywords

• selective internal radiation therapy
• mebrofenin
• hepatobiliary scintigraphy
• liver